

5 neovascularization with the formula of R'-Glu-Trp-R" or pharmaceutically acceptable salts
6 thereof,

7 wherein R' and R" is absent or a moiety independently selected from the group
8 consisting of an amide, an imide, an ester, an anhydride, an ether, a methyl-alkyl ester, an
9 ethyl-alkyl ester, an alkyl group, and an aryl group,

10 wherein R' is present if R" is absent and R" is present if R' is absent,

11 wherein the formula weight of said compound is less than about 5000 Daltons.

1 19. (New) The method of claim 18, wherein the formula weight of said
2 compound is less than about 1000 Daltons.

1 20. (New) The method of claim 18, wherein said compound is selected from
2 the group consisting of:

3 Ac-Glu-Trp, Suc-Glu-Trp, Cpr-Glu-Trp, But-Glu-Trp, and pyroGlu-Trp.

1 21. (New) The method of claim 18, wherein said pharmaceutically
2 acceptable salt is selected from the group consisting of sodium, potassium, ammonium, zinc,
3 magnesium, and calcium.

1 22. (New) The method of claim 18, wherein said pharmaceutically
2 acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, sulfate,
3 bisulfate, acetate, oxalate, valarate, oleate, laurate, borate, benzoate, lactate, phosphate,
4 tosulate, citrate, maleate, fumarate, succinate, and tartrate.

1 23. (New) The method of claim 18, wherein the condition is hemangioma.

1 24. (New) The method of claim 18, wherein the condition is vascularized
2 malignant tumor or vascularized benign tumor.

1 25. (New) The method of claim 24, wherein the tumor is a tumor of the
2 meninges, an intracerebral tumor, a sarcoma, an osteosarcoma, a tumor of the esophagus, or a
3 tumor of the trachea.

1 26. (New) The method of claim 24, wherein the tumor is a Lewis carcinoma.

1 27. (New) The method of claim 24, wherein the tumor is Kaposi's sarcoma.

1 28. (New) The method of claim 18, comprising administering to the subject
2 a dose of said compound of about 0.5 μ g per 1 kilogram body weight to about 1 mg per 1 kg
3 body weight.

1 29. (New) The method of claim 28, wherein the effective amount is about 1
2 μ g/kg to about 50 μ g/kg body weight.

1 30. (New) The method of claim 28, wherein said dose is administered daily
2 over a period of 1 day to about 30 days.

1 31. (New) The method of claim 18, wherein said pharmaceutical preparation
2 is administered intramuscularly, intranasally, transdermally, or intrabronchially.

1 32. (New) The method of claim 18, wherein said pharmaceutical preparation
2 is administered intravenously, intraperitoneally, subcutaneously, or gastrointestinally.

1 33. (New) The method of claim 18, wherein said pharmaceutical preparation
2 is an injectable solution comprising 0.001% to 0.01% of said compound.

1 34. (New) The method of claim 18, wherein said pharmaceutical preparation
2 is in a unit dose form comprising a tablet, a suppository, a capsule, an eye film, an inhalant, a
3 mucosal spray, a nose drop, an eye drop, a toothpaste, an ointment, a water-soluble based
4 cream, a solution, or a saline solution.

1 35. (New) The method of claim 34, wherein said unit dose form consists
2 essentially of 0.01 mg of said compound.

1 36. (New) The method of claim 18, further comprising administering to the
2 subject a vasoactive drug.

1 37. (New) The method of claim 36, wherein the vasoactive drug is an
2 angiotensin converting enzyme (ACE) inhibitor or a potassium channel opener (PCO).

1 38. (New) The method of claim 18, wherein the subject suffers from a tumor
2 and wherein the method further comprises administering a chemotherapeutic agent.

1 39. (New) The method of claim 18, wherein the subject is not immune
2 compromised.

1 39. (New) The method of claim 18, wherein the condition is
2 neovascularization in post-recovery cerebrovascular accident, neovascularization due to head
3 trauma, restenosis following angioplasty, or neovascularization due to heat or cold trauma.

1 41. (New) The method of claim 18, wherein the condition is
2 neovascularization associated with substance-induced neovascularization of the liver,
3 angiogenic dysfunction related to an excess of hormone, neovascular sequelae of diabetes,
4 neovascular sequelae to hypertension, or chronic liver infection.

1 42. (New) The method of claim 41, wherein the neovascular sequelae of
2 diabetes is central serous chorioretinopathy.